PROVENTION BIO INC (PRVB) Fundamental Analysis & Valuation

NASDAQ:PRVB • US74374N1028

24.98 USD
+0.75 (+3.1%)
At close: Apr 26, 2023
25 USD
+0.02 (+0.08%)
After Hours: 4/26/2023, 8:02:36 PM

This PRVB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

PRVB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PRVB have multiple concerns. PRVB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. PRVB Profitability Analysis

1.1 Basic Checks

  • PRVB had negative earnings in the past year.
  • PRVB had a negative operating cash flow in the past year.
PRVB Yearly Net Income VS EBIT VS OCF VS FCFPRVB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • The profitability ratios for PRVB are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PRVB Yearly ROA, ROE, ROICPRVB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

1.3 Margins

  • PRVB's Gross Margin of 96.03% is amongst the best of the industry. PRVB outperforms 96.79% of its industry peers.
  • The Profit Margin and Operating Margin are not available for PRVB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRVB Yearly Profit, Operating, Gross MarginsPRVB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

3

2. PRVB Health Analysis

2.1 Basic Checks

  • PRVB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PRVB has been increased compared to 1 year ago.
  • PRVB has a worse debt/assets ratio than last year.
PRVB Yearly Shares OutstandingPRVB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
PRVB Yearly Total Debt VS Total AssetsPRVB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

  • PRVB has an Altman-Z score of 8.65. This indicates that PRVB is financially healthy and has little risk of bankruptcy at the moment.
  • PRVB's Altman-Z score of 8.65 is amongst the best of the industry. PRVB outperforms 87.61% of its industry peers.
  • A Debt/Equity ratio of 0.19 indicates that PRVB is not too dependend on debt financing.
  • PRVB has a Debt to Equity ratio of 0.19. This is comparable to the rest of the industry: PRVB outperforms 43.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 8.65
ROIC/WACCN/A
WACC8.84%
PRVB Yearly LT Debt VS Equity VS FCFPRVB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

  • PRVB has a Current Ratio of 1.93. This is a normal value and indicates that PRVB is financially healthy and should not expect problems in meeting its short term obligations.
  • PRVB's Current ratio of 1.93 is on the low side compared to the rest of the industry. PRVB is outperformed by 65.60% of its industry peers.
  • A Quick Ratio of 1.92 indicates that PRVB should not have too much problems paying its short term obligations.
  • PRVB's Quick ratio of 1.92 is on the low side compared to the rest of the industry. PRVB is outperformed by 61.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.92
PRVB Yearly Current Assets VS Current LiabilitesPRVB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

5

3. PRVB Growth Analysis

3.1 Past

  • PRVB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.09%, which is quite good.
  • The Revenue has grown by 824.37% in the past year. This is a very strong growth!
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.76%
Revenue 1Y (TTM)824.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1408.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 40.69% on average over the next years. This is a very strong growth
  • PRVB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 138.71% yearly.
EPS Next Y-18.96%
EPS Next 2Y27.12%
EPS Next 3Y36.47%
EPS Next 5Y40.69%
Revenue Next Year372.61%
Revenue Next 2Y275.03%
Revenue Next 3Y253.14%
Revenue Next 5Y138.71%

3.3 Evolution

PRVB Yearly Revenue VS EstimatesPRVB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
PRVB Yearly EPS VS EstimatesPRVB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

1

4. PRVB Valuation Analysis

4.1 Price/Earnings Ratio

  • PRVB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRVB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRVB Price Earnings VS Forward Price EarningsPRVB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRVB Per share dataPRVB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PRVB's earnings are expected to grow with 36.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y36.47%

0

5. PRVB Dividend Analysis

5.1 Amount

  • PRVB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PRVB Fundamentals: All Metrics, Ratios and Statistics

PROVENTION BIO INC

NASDAQ:PRVB (4/26/2023, 8:02:36 PM)

After market: 25 +0.02 (+0.08%)

24.98

+0.75 (+3.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-04
Earnings (Next)08-02
Inst Owners0.27%
Inst Owner Change0%
Ins Owners7.34%
Ins Owner Change0%
Market Cap2.37B
Revenue(TTM)12.89M
Net Income(TTM)-113.56M
Analysts78.33
Price Target24.48 (-2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.45%
Min EPS beat(2)3.79%
Max EPS beat(2)21.1%
EPS beat(4)4
Avg EPS beat(4)15.24%
Min EPS beat(4)3.79%
Max EPS beat(4)26.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)11.53%
Min Revenue beat(2)-4.73%
Max Revenue beat(2)27.78%
Revenue beat(4)2
Avg Revenue beat(4)2.32%
Min Revenue beat(4)-18.77%
Max Revenue beat(4)27.78%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)21.74%
EPS NQ rev (1m)-79.31%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-1.57%
EPS NY rev (3m)-3.75%
Revenue NQ rev (1m)-39.66%
Revenue NQ rev (3m)-12.5%
Revenue NY rev (1m)-22.86%
Revenue NY rev (3m)-17.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 183.61
P/FCF N/A
P/OCF N/A
P/B 19.43
P/tB 38.01
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.14
BVpS1.29
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.03%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.92
Altman-Z 8.65
F-Score2
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)1337.69%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.76%
EPS Next Y-18.96%
EPS Next 2Y27.12%
EPS Next 3Y36.47%
EPS Next 5Y40.69%
Revenue 1Y (TTM)824.37%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1408.09%
Revenue Next Year372.61%
Revenue Next 2Y275.03%
Revenue Next 3Y253.14%
Revenue Next 5Y138.71%
EBIT growth 1Y-10.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.94%
OCF growth 3YN/A
OCF growth 5YN/A

PROVENTION BIO INC / PRVB FAQ

What is the fundamental rating for PRVB stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRVB.


What is the valuation status of PROVENTION BIO INC (PRVB) stock?

ChartMill assigns a valuation rating of 0 / 10 to PROVENTION BIO INC (PRVB). This can be considered as Overvalued.


What is the profitability of PRVB stock?

PROVENTION BIO INC (PRVB) has a profitability rating of 0 / 10.